Alzheimer's Research UK welcomes new Chairman

By Admin
David Mayhew CBE, former chairman of JP Morgan Cazenove, has this week been appointed Chairman of the Board of Trustees of Alzheimers Research UK, the...

David Mayhew CBE, former chairman of JP Morgan Cazenove, has this week been appointed Chairman of the Board of Trustees of Alzheimer’s Research UK, the UK’s leading dementia research charity.

Now Vice Chairman of JP Morgan’s global Investment Bank, Mayhew served as Chairman of the stockbrokers until November last year, and has built up a wealth of experience after more than 40 years with the company.

He officially took up his new role for Alzheimer’s Research UK at the Trustees’ meeting on July 3rdand is now part of the voluntary board; which plays an important strategic role in the charity’s development, overseeing its work and bringing together a wide range of expertise to help in its mission to defeat dementia.

To read the latest edition of Healthcare Global,  click here

Alzheimer’s Research UK is the UK’s leading charity specialising in finding preventions and new treatments for dementia, currently supporting 125 research projects worth over £18 million across the UK Mayhew will strive to help keep the research funding high on the political agenda.

 “I’m delighted to join Alzheimer’s Research UK in this role, and look forward to helping the charity grow and fulfil its mission,” the new Chairman stated.

“Dementia presents an enormous challenge to society, and at a cost of £23 billion a year to the UK economy, it is simply not a problem that can be ignored.

“The only way to tackle the growing challenge of dementia is through research, and I hope I can make a valuable contribution to help the charity achieve its aims.”

Shirley Cramer CBE, Chief Executive at Alzheimer’s Research UK, said: “We’re thrilled to have David joining us. Alzheimer’s Research UK is growing, and with his experience guiding the charity, I’m confident that we can become even more effective as we expand.

“If we are to offer hope to the 820,000 people affected by dementia in the UK, we need to see long-term, sustained investment in research, and this new appointment will be a great boost to help us achieve that goal.”


Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI


Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI